Cephalexin Powder, For Suspension
FDA Label NDC 0093-4175

36 label sections · Submitted to the FDA by Teva Pharmaceuticals Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Pharmaceuticals Usa, Inc. for the product Cephalexin (NDC 0093-4175). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 respiratory tract infections, 1.2 otitis media, 1.3 skin and skin structure infections, 1.4 bone infections, 1.5 genitourinary tract infections, 1.6 usage, 2.1 recommended dosage for adults and pediatric patients at least 15 years of age, 2.2 recommended dosage for pediatric patients (over 1 year of age), and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.